Sagent Pharmaceuticals, an injectable pharmaceutical company with 21 marketed and 45 pipeline products, filed on Monday with the SEC to raise up to $100 million in an initial public offering. The Schaumburg, IL-based company, which was founded in 2006 and booked $50 million in sales for the 12 months ended September 30, plans to list on the NASDAQ under the symbol SGNT. Morgan Stanley, BofA Merrill Lynch and Jefferies & Co. are the lead underwriters on the deal, for which pricing terms and timing were not disclosed.
